Last Updated on February 8, 2020

The following is a letter from Katherine Smith to people in New Zealand considering receiving the H1N1 Swine Flu vaccine.
Please read this letter in full, whether you live in New Zealand or elsewhere. The USA is also mass vaccinating people with this unproven and potentially toxic vaccine. It’s a scam as far as I am concerned. A scam to make money and to control people at a biochemical level. If you can’t get your head around that idea, that’s okay. The facts still remain the same. Please read on…

Dear Friends,

As you probably already know, in February, the Ministry of Health is starting a vaccination campaign against A/H1N1 influenza, despite the fact that cases in NZ long ago peaked and declined. Health professionals will be the first targets of the campaign. The vaccine has also been recommended for pregnant women and will be offered to babies and children aged 6 months to 5 years “enrolled in GP practices in poorer areas or with high proportions of Maori and Pacific Islanders.”

Please find below a letter for health professionals about Baxter’s A/H1N1 influenza vaccine “Celvapan”. The letter details some of my concerns about the vaccine, including the possibility that it may be carcinogenic. Please take the time to read the letter carefully even if you usually support vaccination. I am concerned that the vaccine could pose a risk to the health of recipients, hence my taking the time to write to you. If you agree that the issues that I have discussed in the letter are important, please forward the letter to your family doctor, nurse, and other health professionals you know to warn them about the risks of the vaccine. Most health professionals may take it for granted that the vaccine is safe, when this may not be the case. Your taking the time to warn them will help them make a more informed choice about whether or not to be vaccinated and may prevent them from suffering the potentially serious side effects of this vaccine.

Please also forward this letter to colleagues and friends and family, especially those who are pregnant or who have young children. (If you are unfamiliar with medical terms, you can access an on-line medical dictionary at http://www.nlm.nih.gov/medlineplus/mplusdictionary.html )

Best wishes for a happy, healthy and successful 2010,

Katherine Smith

Could Baxter’s A/H1N1 influenza vaccine (“Celvapan”) endanger your health?

Dear Health Professional,

Please read this letter carefully, regardless of whether or not you support vaccination.

In 2009, the NZ Ministry of Health decided to purchase 300,000 doses of an A/H1N1 influenza vaccine manufactured by Baxter International for targeted distribution to health professionals, police, firefighters and other emergency personnel in the event that the A/H1N1 influenza pandemic warranted its use.
http://www.radionz.co.nz/news/stories/2009/08/06/1245c15c68bd
http://www.moh.govt.nz/moh.nsf/indexmh/influenza-a-h1n1-questions#vaccine (as of 28/10/10)

As you probably know, fears that the new A/H1N1 strain would turn out to be devastating have proved to be largely groundless with NZ’s influenza death rate being comparable to that of seasonal influenza.
http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19319

Baxter International’s recent safety record in the production of biological products is very poor. You may recall the problems with the company’s Heparin in 2008 in which at least four people died due to the product’s being contaminated, while hundreds more became ill as a result of its use.
http://www.medicalnewstoday.com/articles/99662.php

An investigation into this debacle found that Baxter was sourcing raw materials from an uncertified Chinese factory that had never been inspected by the Chinese drug regulators.
http://www.medicalnewstoday.com/articles/97598.php

In February 2009, Baxter distributed to sixteen labs in four different countries a bulk seasonal (H3N2) influenza vaccine product that was contaminated with live bird flu (H5N1) viruses. This could potentially have sparked a deadly H5N1 influenza pandemic, but fortunately staff in a Czech laboratory discovered the problem in time.
http://www. torontosun. com/news/canada/2009/02/27/8560781.html (UPDATE: Toronto Sun have since removed this content from their site)

The Czech Republic subsequently refused to enter into a contract with Baxter for A/H1N1 influenza vaccine as Baxter refused to guarantee the vaccine’s safety nor take responsibility for compensating recipients who might suffer side effects from the vaccine’s use.
http://www.ceskenoviny.cz/tema/zpravy/baxter-not-to-provide-anti-swine-flu-vaccine-to-czechs/391210

Despite having been informed of Baxter International’s recent history of producing contaminated biological products, the New Zealand Ministry of Health maintained its supply contract with Baxter. This decision is currently the subject of a complaint to the Solicitor General – as is the decision to continue a vaccine supply agreement with CSL despite an FDA inspection of its Australian vaccine production factory which found numerous safety code violations.
www .entrepreneur .com/tradejournals/article/202644880.html (This content is no longer found at this link)

Baxter’s A/H1N1 influenza vaccine (“Celvapan”) is produced in “Vero cells” which are derived from green monkey kidney tissue.
http://en.wikipedia.org/wiki/Vero_cell

Cell lines of this type have the potential to be contaminated with viruses such as Simian Virus 40 (SV40) a monkey virus of known oncogenic (tumour producing) potential. (For information about SV40 and cancer in humans please see: http://www.sv40foundation.org/Alexander.html

The Minister of Health responded to a request made under the Official Information Act (OIA) by stating that the Vero cell line used by Baxter has been tested and found to be free from SV40. However, he refused to release the documents necessary to prove this assertion. (This refusal is currently the subject of a complaint to the Ombudsman.)

Moreover, the Vero cell line used to culture the A/H1N1 influenza viruses for Baxter’s “Celvapan” vaccine, is a neoplastic cell line. The FDA is currently investigating whether residual DNA from neoplastic cells (like Vero cells) used in vaccine manufacture can cause cancer in vaccine recipients.

http://www.fda.gov/BiologicsBloodVaccines/ScienceResearch/BiologicsResearchAreas/ucm127304.htm

The NZ Minister of Health is aware of this risk. However, he has no plans to cooperate “at this time” with the US FDA on research on this issue. According to the Minister, the Vero cells line used by Baxter in the production of “Celvapan” is one that minimises the possible cancer risk from the vaccine. However, he refused to release any of the documents to prove this assertion.

Moreover, he stated that the NZ Ministry of Health would not conduct independent testing of Baxter’s A/H1N1 influenza vaccine prior to its use in New Zealand. Such testing could provide vaccine recipients with assurance that the vaccine is not contaminated with H5N1, SV40, any other adventitious microorganisms, oncogenic DNA fragments or any other inadvertent contaminants that could pose a health risk. In other words, The Ministry of Health is relying solely on information supplied by Baxter – which has a massive financial interest in its products – attesting to the safety and efficacy of “Celvapan”. Given the recent history of the company, I don’t find this reassuring, do you?

The datasheet for “Celvapan” is now available on Medsafe’s website. http://www.medsafe.govt.nz/profs/Datasheet/c/Celvapaninj.pdf

It is worth reading to get an idea of the possible side effect profile of Baxter’s influenza vaccine. (Please note that it appears that there are as yet no Phase III trials Baxter’s A/H1N1 influenza vaccine; thus much of the data on the datasheet comes from trials of Baxter’s H5N1 vaccine. Moreover, the Phase III trial of Baxter’s H5N1 has yet to be completed.)
http://clinicaltrials.gov/ct2/show/NCT00711295?term=H5N1+influenza+vaccine+%2B+Baxter&rank=2

Using data from an H5N1 influenza vaccine to justify the use of an H1N1 influenza vaccine was considered acceptable for the registration process, due to the “pandemic”. Potential side effects of concern for Celvapan include sudden hearing loss, paresthesia, arthralgia (from H5N1 influenza vaccine trials) while post marketing surveillance of H1N1 influenza vaccine recipients include convulsions, anaphylaxis and influenza-like illness, among others.

It is also important if you are pregnant (or treat pregnant patients) to realise that according to Baxter’s datasheet there have been no clinical trials on the use of its A/H1N1 influenza vaccine “Celvapan” during pregnancy (or while breastfeeding). This is of concern because pregnant women vaccinated with A/H1N1 influenza vaccines in North America have reported foetal death and miscarriages.
http://preventdisease.com/news/09/110709_H1N1_vaccine_miscarriage_reports.shtml

http://www.theflucase.com/index.php?option=com_content&view=article&id=2593%3Ais-the-h1n1-swine-flu-vaccine-causing-miscarriages&catid=1%3Alatest-news&Itemid=64&lang=en

Another factor to take into account when considering whether or not to be vaccinated with “Celvapan” is that influenza vaccines have a long history of producing disappointing results in terms of preventing influenza or influenza like illness. A recent article published in the British Journal of Medicine stated that:

“In children under 2 years inactivated vaccines had the same field efficacy as placebo,8 and in healthy people under 65 vaccination did not affect hospital stay, time off work, or death from influenza and its complications.9”

The author also expressed surpise at the lack of safety studies:

“A Cochrane Database Systematic Review found only one old trial with data from 35 participants aged 12-28 months.8 In the general population of elderly people, despite a dataset of several million observations, safety was only reported in five randomised controlled trials (2963 observations in total) on local and systemic adverse events seen within a week of giving parenteral inactivated vaccine.”

He recommended that in light of the evidence poor effectiveness of inactivated influenza vaccine, poor methodology of some studies and the surprisingly small amount of information relating to vaccine safety, that a “a re-evaluation [of influenza vaccination programmes] should be urgently undertaken.”

http://www.bmj.com/cgi/content/full/333/7574/912

I hope that this letter gives you some starting points for investigating the A/H1N1 influenza vaccine programme for yourself – or at least gives you some information to help you make a more informed decision about its use.

As someone who is grateful for the excellent care I have received in the NZ public health system (most recently following an accident in which I suffered three fractures) I have the utmost respect for the good work done by health professionals. My aim in writing this letter is to bring your attention to an issue that could be of vital importance to your own health.

Yours sincerely,

Katherine Smith

Further information on the A/H1N1 influenza “pandemic” may be found at www.theflucase.com